2. Academic Validation
  3. Nicotine improves DSS-induced colitis by inhibiting NLRP3 and altering gut microbiota

Nicotine improves DSS-induced colitis by inhibiting NLRP3 and altering gut microbiota

  • J Asian Nat Prod Res. 2024 May;26(5):616-635. doi: 10.1080/10286020.2024.2331773.
Yi-Xiang Zhang 1,  Xiao-Qian Chi 1,  Meng Li 2,  Wei Zhang 2,  Ying Guan 2,  Lian-Qiu Wu 1
Affiliations

Affiliations

  • 1 Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
  • 2 Joint Institute of Tobacco and Health, Research & Development Centre, China Tobacco Yunnan Industrial Co., Ltd., Kunming 650231, China.
PMID: 38655696 DOI: 10.1080/10286020.2024.2331773
Abstract

Ulcerative colitis (UC) is a chronic recurrent inflammatory disease affecting the rectum and colon. Numerous epidemiological studies have identified smoking as a protective factor for UC. Dysbiosis of intestinal microbiota and release of inflammatory factors are well-established characteristics associated with UC. Therefore, we have observed that nicotine exhibits the potential to ameliorate colitis symptoms in UC mice. Additionally, it exerts a regulatory effect on colonic microbiota dysbiosis by promoting the growth of beneficial bacteria while suppressing harmful bacteria. Combined in vivo and in vitro investigations demonstrate that nicotine primarily impedes the assembly of NLRP3, subsequently inhibiting downstream IL-1β secretion.

Keywords

IL-1β; NLRP3; Nicotine; gut microbiota; ulcerative colitis.

Figures
Products